Oxford based Theolytics is leveraging a library of 100M variants of adenoviruses for a bottom up approach to oncolytic virus cancer drug development

CEO David Apelian describes the importance of choosing the right strain for the right type of cancer, and discusses the company's lead program for ovarian cancer.